On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Esteemed Chef Ryan Reed to Develop Signature Edible Cannabis Products for The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF)

  • The signature gourmet edible cannabis products will be launched in the final quarter of 2019
  • Strategic hires as a part of research and development investment have been known to play a primary role in the growth of cannabis industry representatives
  • Flowr Corporation has also announced the engagement of strategic communications and advisory firm ICR as part of the company’s efforts to enhance investor relations and broaden corporate communication

Canadian chef Ryan Reed will be partnering up with The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) on the development of signature edible cannabis products. The Flowr Corporation announced that it would be hiring Reed on March 1, 2019. Hiring a renowned chef enhances the already significant investment that the company has made in research and product development, Flowr Co-CEO Tom Flow said in a company news release (http://ibn.fm/mE2ub).

Ryan Reed is an Iron Chef and Chopped winner. He won the ‘Victoria Chef of the Year’ award in 2011. As part of the collaboration with Flowr, Reed will work with the company’s research and development team to create new, high-quality cannabis edibles. The products are expected to target premium clients, a market that is in line with Flowr’s brand philosophy.

The unique gourmet products are expected to be launched in the final quarter of 2019, following the anticipated legalization of edibles and infused products throughout Canada.

“Bringing Ryan into the fold is the next step in a focused R&D strategy that has created a competitive advantage for Flowr and will keep us on the cutting edge of cannabis innovation,” Flowr chief policy and medical officer Dr. Lyle Oberg said in a news release.

According to Reed, a kitchen and a cultivation facility both need leaders with technical mastery to promote innovation. Working with Tom Flow and the Flowr team is expected to result in gourmet, sophisticated edibles that will cater to the needs of the premium market, Reed concluded.

Analytical reports suggest that an investment in research and development, including strategic hires, ranks among the factors that create the most value for cannabis companies. Flowr has fully embraced this philosophy, and the latest corporate developments stand as evidence of the company’s plans for strategic growth.

Apart from announcing the partnership with Reed, Flowr Corporation has also released information about the engagement of ICR for the purpose of enhancing the company’s investor relations.

ICR is a leading strategic communications and advisory firm. ICR’s financial media expertise and extensive knowledge in the cannabis sector are expected to improve Flowr’s communication with stakeholders and investors, Flow said. In addition, ICR will be tasked with broadening the financial community’s understanding of the differentiated Flowr business model, he underlined. Over the coming six months, ICR will provide comprehensive investor relations management and corporate communication services.

The Flowr Corporation is a Health Canada licensed producer of premium cannabis products. The company was co-founded by MedReleaf co-founder Tom Flow and a team of industry pioneers. The corporation’s purpose-built cultivation facilities rank among the most advanced in the industry, resulting in high crop yield for the creation of premium and ultra-premium cannabis products.

For more information, visit the company’s website at www.Flowr.ca

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.